Stakeholder Opinions: Ophthalmology - Leading brands under threat - Market Research Reports On Aarks

June 25, 2010 - PRLog -- Introduction

Ophthalmology encompasses some lucrative markets, but the future of leading brands in glaucoma and AMD is under threat, and while established markets like glaucoma and conjunctivitis have many therapeutic options, diabetic retinopathy remains largely untapped. Key opinion leaders agree there is unmet need in terms of drug delivery methods and dose frequency across ophthalmology diseases.

Scope

*Snapshot of ophthalmology diseases based on the worldwide leading causes of blindness

*Review of current treatment options, and epidemiology in eye diseases in each of the seven major markets and selected rest of the world regions

*Analysis of ophthalmology ATC drug classes with assessment of key brand and country dynamics

*Assessment of unmet needs based on key opinion leader interviews and a review of pipeline therapies in leading ophthalmic diseases

Highlights

The future of leading brands Lucentis (ranibizumab) and Xalatan (latanoprost) is at risk. Lucentis dominates AMD with 91% market share but the use of currently off-label Avastin (bevacizumab, Roche) is a threat. Xalatan, the gold standard in glaucoma achieved $1.5 billion in 2008 but the drug faces generic erosion after patent expiry in 2011

Diabetic retinopathy and AMD markets show high growth potential. Both diseases are highly prevalent, with 11.5 million cases of diabetic retinopathy, and 7.5 million in AMD, in the seven major markets in 2010. There are few drug treatments for AMD, while no approved drugs for diabetic retinopathy mean this market is untapped.

Key opinion leaders report high unmet need for reduced dosing regimens of existing therapies and an improvement in drug delivery methods. However, any new formulations of existing drugs will have to compete with cheap generics and need to show significant additional benefits.

Reasons to Purchase

*Validate the market potential of particular ophthalmology indications based on prevalence numbers in each of the seven major markets

*Understand the commercial potential of ophthalmic diseases with Datamonitor’s assessment of market and brand dynamics

*Assess the key unmet needs and possible new approaches in the treatment of eye diseases as noted by opinion leaders
    

Table of Contents :

"Overview 1
Catalyst 1
Summary 1
About healthcare 2
About the Immunology & Inflammation pharmaceutical analysis team 2
Executive Summary 3
Scope of the analysis 3
insight into the ophthalmology market 3
Table of Contents 5
Chapter 1. Overview of the ophthalmology market 6
Key findings of the ophthalmology market 6
Introduction to ophthalmology and the human eye 7
Ophthalmology market attractiveness 11
ophthalmology market definition 11
Therapeutic sales for ophthalmology disorders exceeded $12 billion in 2008 12
High growth potential observed in diabetic retinopathy and age-related macular degeneration markets 13
Age-related macular degeneration shows a high growth rate, and seemingly unsaturated market 15
Middle Eastern, North African (MENA) and Brazil, Russia, India and China (BRIC) ophthalmology markets are growing rapidly 16
Brand and company dynamics in ophthalmology 19
Current leading brands Lucentis and Xalatan are both under threat 19
Lucentis versus Avastin in the treatment of age-related macular degeneration (AMD) 19
Xalatan sales set to decline with looming patent expiry in 2011 21
Established eye care companies within the ophthalmology market 22
Future of the ophthalmology market 24
Reducing the dosing frequency and improving current drug delivery methods are key unmet needs 24
High pipeline potential in diabetic retinopathy and age-related macular degeneration (AMD) 25
Chapter 2. Glaucoma 29
Key findings 29
Definition and classification of glaucoma 30
Primary open-angle glaucoma (POAG) 30
Angle-closure glaucoma (ACG) 30
Primary angle-closure glaucoma 30
Secondary angle-closure glaucoma 31
Normal tension and secondary glaucoma 31
Risk factors associated with glaucoma 31
Epidemiology of glaucoma 32
Total glaucoma patient potential is up to 7.0 million in the seven major markets in 2010 32
estimates 5.4 million primary open-angle glaucoma sufferers across the seven major markets in 2010 34
Assumptions and limitations in estimating the primary open-angle glaucoma population in the seven major markets 35
Primary open-angle glaucoma is more prevalent in older US females 35
Prevalence of primary open-angle glaucoma in different racial groups 37
Epidemiology of primary angle-closure glaucoma in the seven major markets 38
Epidemiology of other types of glaucoma in the seven major markets 39
Epidemiology studies of glaucoma in the seven major markets 39
Prevalence of glaucoma in India and China is similar to that of the seven major markets 43
Current treatment options in glaucoma 46
Overview of treatments in glaucoma 46
Beta-blockers 50
Prostaglandin analogs 50
Alpha-agonists 50
Carbonic anhydrase inhibitors 51
Miotics 51
Hyperosmotic agents 51
Glaucoma treatment guidelines 51
Diagnosing glaucoma 51
Sales analysis of brands in glaucoma 54
Global glaucoma market reached over $5 billion sales in 2008 54

For more information please visit :

http://www.aarkstore.com/reports/Stakeholder-Opinions-Oph...

# # #

Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.